title: Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
abstract: BACKGROUND
  There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h) nucleoside analogues in HIV-infected children.
  
  
  METHODS
  Children aged 2-13 years receiving combination treatment containing lamivudine (3TC) (4 mg/kg) and/or abacavir (ABC) (8 mg/kg) twice daily (q12h) were included in this single-arm, open-label, crossover study. Intensive plasma PK sampling was performed at steady state, after which children switched to q24h dosing and PK sampling was repeated 4 weeks later. Daily area under the curve (AUC0-24) and peak level (Cmax) of q24h and q12h regimens were compared by geometric mean ratios (GMRs) with 90% confidence intervals (CIs). Children were followed for 24 weeks to evaluate safety and virological response.
  
  
  RESULTS
  24 children were enrolled, of whom 20 [median age (range) 5.6 (2.1-12.8) years] had evaluable PK data for 3TC (n=19) and/or ABC (n=14). GMRs of 3TC and ABC AUC0-24 and Cmax q24h versus q12h significantly exceeded 1.0. GMRs were not significantly different between children aged 2-6 versus 6-13 years old (P>0.08). Of note, 3TC Cmax values for both q12h and q24h were significantly lower in children aged 2-6 versus 6-13 years old. No child discontinued due to adverse events. At baseline, 16 out of 20 children had a viral load <100 copies/ml compared with 17 out of 19 at week 24.
  
  
  CONCLUSIONS
  AUC0-24 and Cmax of both 3TC and ABC q24h were not inferior to q12h dosing in children. Insufficient results were obtained concerning intracellular levels of the active triphosphate moieties of both agents. Virological data did not indicate a marked difference in antiviral activity between q12h and q24h regimens.
authors.affiliation: Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.
authors.forename: Alina
authors.initials: A
authors.lastname: Bergshoeff
authors.forename: David
authors.initials: D
authors.lastname: Burger
authors.forename: Corrien
authors.initials: C
authors.lastname: Verweij
authors.forename: Laura
authors.initials: L
authors.lastname: Farrelly
authors.forename: Jacquie
authors.initials: J
authors.lastname: Flynn
authors.forename: Marthe
authors.initials: M
authors.lastname: Le Prevost
authors.forename: Sarah
authors.initials: S
authors.lastname: Walker
authors.forename: Vas
authors.initials: V
authors.lastname: Novelli
authors.forename: Hermione
authors.initials: H
authors.lastname: Lyall
authors.forename: Saye
authors.initials: S
authors.lastname: Khoo
authors.forename: Di
authors.initials: D
authors.lastname: Gibb
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D015224:Dideoxynucleosides / Q000494:pharmacology* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D015497:HIV-1; D006801:Humans; D007223:Infant; D019259:Lamivudine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D009426:Netherlands; D006113:United Kingdom; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D019259:Lamivudine; D000099227:Abacavir